Promore Pharma AB (publ) Interim report January – September 2019
June – September · Net sales amounted to 1,3 (1,0) MSEK. · The operating loss for the period was 6,7 (-7,4)MSEK · Net loss was 6,7 (-7,6) MSEK corresponding to earnings per share of SEK -0,33 (-0,38) · Cash flow from operating activities amounted to -6,9 (-6,7) MSEK · Cash and cash equivalents amounted to 13,0 (39,5) MSEK January – September · Net sales amounted to 2,5 (1,1) MSEK · The operating loss for the period was 19,6(-26,1) MSEK · Net loss was 19,5 (-25,3) MSEK corresponding to earnings per share of SEK -0,96 (-1,25) · Cash flow from operating